Enhanced, Simplified Glucose Sensors: Long‐Term Clinical Application of Wearable Artificial Endocrine Pancreas
| Autor: | Seiya Shimoda, Kenro Nishida, Michiharu Sakakida, Motoaki Shichiri |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Blood Glucose
medicine.medical_specialty Microdialysis Metallocenes Phosphorylcholine Biomedical Engineering Medicine (miscellaneous) Bioengineering Biosensing Techniques Hypoglycemia Biomaterials Insulin Infusion Systems In vivo Internal medicine Diabetes mellitus medicine Hyperinsulinemia Animals Humans Insulin Insulin lispro Ferrous Compounds Randomized Controlled Trials as Topic Artificial endocrine pancreas Glycemic Insulin Lispro business.industry Blood Glucose Self-Monitoring Membranes Artificial General Medicine medicine.disease Rats Diabetes Mellitus Type 1 Endocrinology Diabetes Mellitus Type 2 Polyvinyl Alcohol Methacrylates business medicine.drug |
| Zdroj: | Artificial Organs. 22:32-42 |
| ISSN: | 1525-1594 0160-564X |
| DOI: | 10.1046/j.1525-1594.1998.06043.x |
| Popis: | At present, 2 major problems should be solved before long-term application of the wearable artificial endocrine pancreas, the development of a reliable and stable glucose monitoring system and the development of a subcutaneous insulin infusion algorithm. With either a miniaturized extracorporeal glucose monitoring system based on microdialysis sampling method or a ferrocene-mediated needle-type glucose sensor covered with highly biocompatible membrane, poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) (poly[MPC-co-BMA]) membrane, subcutaneous glucose concentrations could be monitored for 7 days without any in vivo calibrations, followed by 14 days with one point calibration. Considering the management and safety of the insulin delivery route, subcutaneous insulin infusion is obligatory. With the subcutaneous insulin infusion algorithm using a short acting insulin analogue (Insulin Lispro), near physiological glycemic control could be established in diabetic patients without showing any delayed hyperinsulinemia or hypoglycemia. The wearable artificial endocrine pancreas is now recognized as an excellent therapeutic tool for regulating blood glucose excursions physiologically in ambulatory diabetic patients on a long-term basis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|